Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he plans to expand prescribing of GLP-1 medications beyond specialist weight-management services.

National Institute for Health and Care Excellence (NICE) guidance on the first two GLP-1 medicines licensed for the treatment of obesity, namely liraglutide under various brand names and semaglutide with brand name Wegovy, restricted their use to specialist weight management services. These services are primarily delivered in secondary care.

NICE recommended that tirzepatide, with brand name Mounjaro, could be used for the treatment of obesity in eligible patients without a restriction on its setting. This means tirzepatide can be used in specialist weight management services but can also be prescribed in primary care by general practitioners (GPs) and other competent prescribers. From 23 June 2025, tirzepatide started to become available in primary care so the expansion beyond specialist services is underway.

Integrated care boards (ICBs) are the National Health Service organisations responsible for arranging the provision of health services within their area in line with local population need and taking account of relevant guidance. ICBs have had to develop new care pathways to ensure that patients can access these medicines via their GP with appropriate wraparound support. NHS England has been working closely with ICBs to support the safe and effective roll out of tirzepatide in primary care. It has identified the groups of people to be prioritised in each phase of the initial rollout; helped develop local treatment models; provided funding support and regular communication channels to ICBs; and set up an interim, centrally funded ‘wraparound care service’, known as the ‘Healthier You: Behavioural Support for Obesity Prescribing’, for patients to be referred into, with a procurement underway for a longer-term offer.